Gabriel N. Hortobágyi
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
Papers in
- Cancer Research 400
- Breast Cancer Treatment Studies 355
- Cancer Genomics and Diagnostics 43
- Oncology 533
- Cancer Treatment and Pharmacology 189
- HER2/EGFR in Cancer Research 172
- Cancer Cells and Metastasis 56
- Co-authors
- Aman U. Buzdar (220 shared papers)Vicente Valero (176 shared papers)Lajos Pusztai (134 shared papers)Ana Maria Gonzalez-Angulo (109 shared papers)Sharon Hermes Giordano (55 shared papers)W. Fraser Symmans (89 shared papers)Thomas A. Buchholz (104 shared papers)Massimo Cristofanilli (89 shared papers)
- Journals
- Cancer (152 papers)Journal of Clinical Oncology (146 papers)Breast Cancer Research and Treatment (58 papers)The Oncologist (47 papers)Clinical Cancer Research (41 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Gabriel N. Hortobágyi
1.1k papers receiving 108.3k citations
Gabriel N. Hortobágyi's Hit Papers
Peers
Comparison fields: 5 of 204
- Cancer Research 37.6k
- Oncology 51.4k
- Pulmonary and Respiratory Medicine 18.0k
- Pathology and Forensic Medicine 8.8k
- Radiology, Nuclear Medicine and Imaging 9.2k
Countries citing papers authored by Gabriel N. Hortobágyi
This map shows the geographic impact of Gabriel N. Hortobágyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel N. Hortobágyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel N. Hortobágyi more than expected).
Fields of papers citing papers by Gabriel N. Hortobágyi
This network shows the impact of papers produced by Gabriel N. Hortobágyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel N. Hortobágyi. The network helps show where Gabriel N. Hortobágyi may publish in the future.
Co-authors
The 25 scholars most cited alongside Gabriel N. Hortobágyi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.1k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2011 | 2395 |
| 2 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Hit paper breakdown → | 2008 | 2387 |
| 3 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Hit paper breakdown → | 2016 | 1544 |
| 4 | PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Hit paper breakdown → | 2004 | 1522 |
| 5 | Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Hit paper breakdown → | 2005 | 1519 |
| 6 | Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation Hit paper breakdown → | 2009 | 1450 |
| 7 | Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy Hit paper breakdown → | 2007 | 1306 |
| 8 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Hit paper breakdown → | 2009 | 1150 |
| 9 | Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy Hit paper breakdown → | 1999 | 1138 |
| 10 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer Hit paper breakdown → | 2013 | 1014 |
| 11 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 971 |
| 12 | Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer Hit paper breakdown → | 2005 | 958 |
| 13 | The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine Hit paper breakdown → | 2009 | 951 |
| 14 | Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer Hit paper breakdown → | 2005 | 946 |
| 15 | Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity Hit paper breakdown → | 2016 | 902 |
| 16 | Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases Hit paper breakdown → | 1996 | 855 |
| 17 | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Hit paper breakdown → | 2017 | 840 |
| 18 | Overview of Resistance to Systemic Therapy in Patients with Breast Cancer Hit paper breakdown → | 2007 | 756 |
| 19 | Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer Hit paper breakdown → | 2009 | 749 |
| 20 | THE IMPACT OF NATIONAL CANCER ACT Hit paper breakdown → | 1991 | 743 |
About Gabriel N. Hortobágyi
Gabriel N. Hortobágyi is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 1.1k papers that have together received 112.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (355 papers), Cancer Treatment and Pharmacology (189 papers), HER2/EGFR in Cancer Research (172 papers), Cancer Cells and Metastasis (56 papers), Advanced Breast Cancer Therapies (54 papers), Breast Lesions and Carcinomas (48 papers), Cancer Genomics and Diagnostics (43 papers) and Estrogen and related hormone effects (41 papers). The work is most often cited by research in Cancer Research (37.6k citations), Oncology (51.4k citations), Pulmonary and Respiratory Medicine (18.0k citations), Pathology and Forensic Medicine (8.8k citations) and Radiology, Nuclear Medicine and Imaging (9.2k citations). Gabriel N. Hortobágyi has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Aman U. Buzdar, Vicente Valero, Lajos Pusztai, Ana Maria Gonzalez-Angulo, Sharon Hermes Giordano, W. Fraser Symmans, Thomas A. Buchholz, Massimo Cristofanilli, Francisco J. Esteva and Richard L. Theriault. Their work appears in journals such as Cancer, Journal of Clinical Oncology, Breast Cancer Research and Treatment, The Oncologist and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.